tiprankstipranks
Anthera Pharmaceuticals (ANTH)
OTHER OTC:ANTH
US Market

Anthera Pharmaceuticals (ANTH) Stock Price & Analysis

232 Followers

ANTH Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range― - ―
Previous Close$0.03
Volume2.50K
Average Volume (3M)N/A
Market Cap
$26.00
Enterprise Value-$8.09M
Total Cash (Recent Filing)$8.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta-16.54
Mar 05, 2018
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,179,302
10 Day Avg. Volume250
30 Day Avg. VolumeN/A
Standard Deviation29.81
R-Squared0.05
Alpha7.72
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

86.26%0.00%0.04%13.70%
86.26%
Insiders
0.04% Other Institutional Investors
13.70% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

ANTH FAQ

What was Anthera Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Anthera Pharmaceuticals’s market cap?
Currently, no data Available
When is Anthera Pharmaceuticals’s upcoming earnings report date?
Anthera Pharmaceuticals’s upcoming earnings report date is Mar 05, 2018 which is 2206 days ago.
    How were Anthera Pharmaceuticals’s earnings last quarter?
    Anthera Pharmaceuticals released its earnings results on Nov 06, 2017. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.58.
      Is Anthera Pharmaceuticals overvalued?
      According to Wall Street analysts Anthera Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Anthera Pharmaceuticals pay dividends?
        Anthera Pharmaceuticals does not currently pay dividends.
        What is Anthera Pharmaceuticals’s EPS estimate?
        Anthera Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Anthera Pharmaceuticals have?
        Anthera Pharmaceuticals has 26,179,000 shares outstanding.
          What happened to Anthera Pharmaceuticals’s price movement after its last earnings report?
          Anthera Pharmaceuticals reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
            Which hedge fund is a major shareholder of Anthera Pharmaceuticals?
            Currently, no hedge funds are holding shares in ANTH
            ---

            Anthera Pharmaceuticals Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Company Description

            Anthera Pharmaceuticals

            Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Antigenics
            Karyopharm Therapeutics
            Xencor
            AN2 Therapeutics, Inc.
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis